Abstract:Introduction The Clinical High Risk (CHR) group for transition to psychotic disorders (PD) is usually defined by the severity of positive symptoms, help-seeking and impairment in level of functioning. However, the CHR concept has a limited transition risk to PD. Recent studies have shown that some of the risks might be attributable to other symptoms. Objectives This study investigates the association between affective and negative symptoms and the risk of transition to PD in a community-based population of 2185 participants in Turkey. Methods At baseline, psychotic and affective symptomatology were assessed. The same participants were contacted again 6-years later. The initial analysis aimed to assess the link between affective and negative symptoms, and the progression to PD. The independent variable, baseline symptomatology, was categorized into five groups: no Psychotic Experiences (PE)(reference), subclinical PE, subclinical PE accompanied by affective/negative symptoms, clinical PE, and clinical PE with affective/negative symptoms. In the subsequent analysis, the association between affective and negative symptoms at baseline and the onset of PE and PD at follow-up was evaluated. For this analysis, the baseline symptomatology was restructured into two categories: neither PE nor affective/negative symptoms (reference), and the presence of affective/negative symptoms without PE. Results The findings from the initial analysis indicated that being part of the 'subclinical PE only' group at baseline was not associated with an increased risk of developing PD at follow-up. Being part of the 'subclinical PE+affective/negative symptoms' group was not significantly associated with PD at follow-up, although a trend was observed (OR: 3.22; z=1.90; p=0.057). Moreover, being classified as having 'clinical PE only' (OR: 6.23; z=2.57; p=0.010) and 'clinical PE+affective/negative symptoms' (OR: 8.48; z=4.17; p=0.001) at baseline was associated with an increased risk of developing PD at follow-up. Results from the subsequent analysis showed that being in the 'affective/negative symptoms' group at baseline was associated with an increased risk of new subclinical PE (RR: 1.98; z=3.20; p=0.001), new clinical PE (RR: 3.14; z=4.84; p=0.001), and new PD (RR: 4.21; z=2.17; p=0.030) at follow-up, compared to the 'neither PE nor affective/negative symptoms' group. Conclusions The results confirm that baseline severity of positive symptoms is significant in predicting transition to PD. In addition, the findings imply that not only positive symptoms but also affective and negative symptoms might contribute to the risk of transition to PD as well as incident psychotic symptoms. Defining CHR groups based on a combination of positive, affective and negative symptoms instead of focusing only on positive symptoms likely will help more accurately predict the transition to psychosis. Disclosure of Interest None Declared

Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk

Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study

Antipsychotic Exposure in Clinical High Risk of Psychosis

Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period

Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High Risk for Psychosis

Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High-Risk for Psychosis

Further Evidence That Antipsychotic Medication Does Not Prevent Long-Term Psychosis in Higher-Risk Individuals

Antipsychotic Prescription, Assumption and Conversion to Psychosis: Resolving Missing Clinical Links to Optimize Prevention Through Precision

Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice

Real-world Effectiveness of Antipsychotic Treatment in Psychosis Prevention in a 3-Year Cohort of 517 Individuals at Clinical High Risk from the SHARP (shanghai at Risk for Psychosis).

The impact of affective and negative symptoms on the development of psychosis in a six-year follow-up of a community-based population

Physical Health and Transition to Psychosis in People at Clinical High Risk

Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis

Individualized Risk Components Guiding Antipsychotic Delivery in Patients with a Clinical High Risk of Psychosis: Application of a Risk Calculator

Clinical and neurodevelopmental predictors of psychotic disorders in children and adolescents at clinical high risk for psychosis: the CAPRIS study

Are factors that predict conversion to psychosis associated with initial transition to a high risk state? An adolescent brain cognitive development study analysis

Duration of Untreated Prodromal Psychosis among Individuals with Clinical High Risk for Psychosis.

When to Initiate Antipsychotic Treatment for Psychotic Symptoms: at the Premorbid Phase or First Episode of Psychosis?

Antipsychotic Treatment Effects on Progression of Brain Pathomorphology in First Episode Schizophrenia

Previous Exposure to Antipsychotic Drug Treatment is an Effective Predictor of Metabolic Disturbances Experienced with Current Antipsychotic Drug Treatments

A proposal for reducing maximum target doses of drugs for psychosis: Reviewing dose–response literature